It's been a horrible, lousy, rotten year so far for Alnylam Pharmaceuticals (NASDAQ: ALNY) investors. Feel free to add any other similar adjectives you'd like. Alnylam's share price has plunged more than 40% year to date. Only one other large-cap stock in the entire healthcare sector has performed worse. Alnylam's impressive 69% gain in 2025 has been almost completely erased. The drugmaker's financials look great. It's now solidly profitable. But investors are clearly treating Alnylam like it's a broken biotech stock.
CryptoAlerta — análise de criptomoedas e mercado em tempo real